Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 15, 2011
Event Date: March 14, 2011
Context: The Company entered into a global settlement agreement resolving ongoing litigation regarding the "Tuschl" patents with Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V., Max Planck Innovation GmbH, the Whitehead Institute for Biomedical Research, and the University of Massachusetts (UMass). The Massachusetts Institute of Technology (MIT) also agreed to the terms.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on a legal settlement rather than financial performance results.
Material Changes and Settlement Terms
- Resolution of Litigation: The agreement resolves litigation initiated in June 2009 regarding the prosecution of Tuschl I and Tuschl II patent applications. All claims and counterclaims are mutually released and dismissed with prejudice.
- Patent Prosecution Leadership:
- Max Planck: Will lead future prosecution of Tuschl I and Tuschl II patent families in the United States and continue leading Tuschl II prosecution outside the U.S.
- UMass: Will lead future prosecution of the Tuschl I patent family outside the United States.
- Sublicensing Rights: The Company granted UMass the right to sublicense the U.S. Tuschl II patent family to Merck & Co., Inc., subject to certain obligations. In exchange, UMass will receive a share of certain future sublicense income.
Outlook, Risks, and Unusual Items
Cost Disclosure: The Company is currently determining the costs incurred during the three months ended March 31, 2011, related to this dispute. These costs will be charged to general and administrative expense and disclosed in the upcoming Quarterly Report on Form 10-Q for the period ended March 31, 2011.
Risk Mitigation: The settlement eliminates the uncertainty of a trial scheduled for March 2011 and clarifies the governance of critical RNAi therapeutic patents.
Investor Verification Checklist
- Verify the specific financial impact of the settlement costs in the upcoming Form 10-Q for the quarter ended March 31, 2011.
- Confirm the terms of the sublicense agreement with Merck & Co., Inc. regarding the U.S. Tuschl II patent family.
- Monitor the progress of coordinated patent prosecution led by Max Planck and UMass to ensure protection of the Company's exclusive license rights.